#### ACURA PHARMACEUTICALS, INC

Form 4

January 27, 2014

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

**SECURITIES** 

**OMB** Number:

3235-0287

**OMB APPROVAL** 

Expires:

January 31, 2005

0.5

Estimated average

burden hours per

response...

Check this box if no longer subject to Section 16. Form 4 or

Form 5 obligations may continue. See Instruction

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section

30(h) of the Investment Company Act of 1940

1(b).

(Print or Type Responses)

1. Name and Address of Reporting Person \* **EMIGH JAMES F** 

(First)

(Street)

2. Issuer Name and Ticker or Trading

5. Relationship of Reporting Person(s) to Issuer

below)

Symbol

ACURA PHARMACEUTICALS, INC [ACUR]

(Check all applicable)

VP Corporate Development

(Middle)

(Zip)

(Month/Day/Year) Execution Date, if

2. Transaction Date 2A. Deemed

3. Date of Earliest Transaction (Month/Day/Year)

Director 10% Owner X\_ Officer (give title Other (specify

C/O ACURA PHARMACUTICALS, 01/24/2014

INC., 616 N. NORTH COURT,

**SUITE 120** 

1.Title of

Security

(Instr. 3)

(Last)

4. If Amendment, Date Original

(Instr. 8)

6. Individual or Joint/Group Filing(Check

Filed(Month/Day/Year)

Applicable Line) \_X\_ Form filed by One Reporting Person Form filed by More than One Reporting

PALATINE, IL 60067

(City) (State)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

3. 4. Securities

TransactionAcquired (A) or Code Disposed of (D)

(Instr. 3, 4 and 5)

5. Amount of 6. Ownership 7. Nature of Securities Form: Direct Indirect Beneficially (D) or Beneficial Owned Indirect (I) Ownership Following (Instr. 4) (Instr. 4)

D

Reported (A) Transaction(s)

(Instr. 3 and 4)

Code V Amount (D) Price

Common 01/24/2014 Stock

183,304

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

(Month/Day/Year)

Persons who respond to the collection of SEC 1474 information contained in this form are not (9-02)required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

### Edgar Filing: ACURA PHARMACEUTICALS, INC - Form 4

2.	3. Transaction Date	3A. Deemed	4.	5. Number	6. Date Exercisab	le and	7. Title and A	Amount of
Conversion	(Month/Day/Year)	Execution Date, if	Transaction Derivative		Expiration Date		<b>Underlying Securities</b>	
or Exercise		any	Code	Securities	(Month/Day/Year	•)	(Instr. 3 and	4)
Price of		(Month/Day/Year)	(Instr. 8)	Acquired				
Derivative				(A) or				
Security				Disposed of				
				(D)				
				(Instr. 3, 4,				
				and 5)				
								Amount
					Data Evansiaabla	Expiration	Title	or Number
					Date Exercisable	Date	Title	of
			Codo V	(A) (D)				-
			Code v	(A) (D)				Shares
					0.1.0.1.5.0.1.(1)		Common	
\$ 1.3	01/24/2014		M	6,225	01/01/2014 <u>(1)</u>	03/09/2014	Stock	6,225
1	Conversion or Exercise Price of Derivative	Conversion (Month/Day/Year) or Exercise Price of Derivative Security	or Exercise any Price of (Month/Day/Year) Derivative Security	Conversion (Month/Day/Year) Execution Date, if Transaction Exercise any Code (Month/Day/Year) (Instr. 8)  Derivative Security  Code V	Conversion (Month/Day/Year) Execution Date, if any Code Securities  Price of (Month/Day/Year) (Month/Day/Year) (Instr. 8) Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)  Code V (A) (D)	Conversion (Month/Day/Year) Execution Date, if any Code Securities (Month/Day/Year) (Instr. 8) Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)  Date Exercisable  Code V (A) (D)	Conversion (Month/Day/Year) Execution Date, if any Code Securities (Month/Day/Year) (Month/Day/Year) (Instr. 8) Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)  Code V (A) (D)  Expiration Date (Month/Day/Year)  Expiration Date (Month/Day/Year)  Code V (A) (D)  Expiration Date (Month/Day/Year)  Date Exercisable Expiration Date (Month/Day/Year)  Date Exercisable Code V (A) (D)	Conversion (Month/Day/Year) Execution Date, if any (Month/Day/Year) (Instr. 3 and Price of Derivative Security (Month/Day/Year) (Instr. 8) Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)  Date Exercise Expiration Date (Month/Day/Year) (Instr. 3 and Price of (Instr. 3) Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)  Date Exercisable Expiration Date (Instr. 3) Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)  Date Exercisable Common Title  Code V (A) (D)  Standard Common Common (Instr. 3) Acquired (Month/Day/Year) (Instr. 3) Acquired (A) or Disposed of (D) (Instr. 3) Acquired (D) (Instr. 3) Acquired (Month/Day/Year) (In

## **Reporting Owners**

Reporting Owner Name / Address

Relationships

Director 10% Owner Officer Other

EMIGH JAMES F C/O ACURA PHARMACUTICALS, INC. 616 N. NORTH COURT, SUITE 120 PALATINE, IL 60067

VP Corporate Development

## **Signatures**

/s/ James Emigh 01/27/2014

\*\*Signature of Person Date

Reporting Person

# **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- Option is exercisable with respect to remaining 6,225 shares being exercised herewith commencing January 1, 2014. Option was previously exercised for 18,675 shares, which became exercisable in installments in prior years.
- (2) N/A

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 2